Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Tribunal sided with generic makers of Olmetec Plus
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jun 18, 2014 14:35:57
Intellectual Property Tribunal sided with seventeen generic drugmakers of Olmetec Plus, ruling that Daiichi Sankyo’s patent of the composition of Olmetec Plus is invalid.

That patent was supposed to expire in 2021, but some generic versions had been already rolled out since Olmetec went off patent last fall.

A patent specialist of a Korean pharmaceutical company said, “I expected Korean drugmakers would win the patent case. As the tribunal sided with Korean companies, they are now free from patent issues.”

More than a half of the products containing olmesartan come with other active ingredients.

Seventeen companies include Dong-A ST, JW Choongwae, Kukjei, JRP, Kolon, Ahngook, Pharmaking, Ilayng, Ildong, Chong Kun Dang and so on.

Daiichi Sankyo may seek appeal later.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com